Beijing Four Rings Biopharmaceutical

Beijing Four Rings Biopharmaceutical is a pioneering Chinese biotechnology company specializing in the development and manufacture of recombinant protein drugs. Established in 1988, it was one of the first high-tech enterprises in China to focus on genetic engineering and the first to industrialize recombinant human Interleukin-2. The company's product portfolio primarily includes cytokines and hematological agents such as Interleukin-2, Interferon alpha-2b, G-CSF, and Erythropoietin. It operates as a core subsidiary of the publicly traded Jiangsu Sihuan Bioengineering Co., Ltd. and maintains large-scale GMP-certified manufacturing facilities in Beijing. The company remains a significant player in the domestic market for biologics targeting cancer and infectious diseases.